Atlas Trials

Imaging With a New Agent That Finds a Cancer Protein Called HER2

Clinical trial NCT03109977 · COMPLETED

Trial details

NCT number
NCT03109977
Sponsor
Memorial Sloan Kettering Cancer Center
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
HER2-positive CarcinomaHER2-positive Primary Malignancy
Start date
2017-03-31
Primary completion
2018-04-12
Enrollment
6

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.